c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation

Cancer Research

Volumn 68, Issue 7, 2008, Pages 2166-2175

  Lotan, Tamara ^a   Hickson, Jonathan ^a   Souris, Jeffrey ^a   Huo, Dezheng ^a   Taylor, Jennifer ^a   Li, Terry ^a   Otto, Kristen ^a   Yamada, Seiko Diane ^a,b   Macleod, Kay ^a,c   Rinker Schaeffer, Carrie W ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b University of Chicago   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 4; MITOGEN ACTIVATED PROTEIN KINASE P38; P21 ACTIVATED KINASE; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE 1; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; HEMAGGLUTININ; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; ANIMAL; APOPTOSIS; BIOLOGICAL MODEL; BIOSYNTHESIS; CELL ADHESION; ENZYMOLOGY; GENETICS; METABOLISM; NUDE MOUSE; OMENTUM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TRANSGENE; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL ADHESION; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HEMAGGLUTININS; HUMANS; MAP KINASE KINASE 4; MICE; MICE, NUDE; MITOGEN-ACTIVATED PROTEIN KINASE 8; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; OMENTUM; OVARIAN NEOPLASMS; TRANSGENES; UP-REGULATION;

EID: 42049120920     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1568     Document Type: Article

References (39)

1. Cancer facts & figures 2007. Atlanta: American Cancer Society; 2007.
2. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
3. Pantel K, Alix-Panabieres C. The clinical significance of circulating tumor cells. Nat Clin Pract Oncol 2007;4:62-3.
4. Chambers AF, Groom AC, MacDonald IC. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-72.
5. Rinker-Schaeffer CW, O'Keefe JP, Welch DR, et al. Metastasis suppressor proteins: discovery, molecular mechanisms, and clinical application. Clin Cancer Res 2006;12:3882-9.
6. Yamada SD, Hickson JA, Hrobowski Y, et al. Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res 2002;62:6717-23.
7. Kyriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001;81:807-69.
8. Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-83.
9. Yu D, Wolf JK, Scanlon M, et al. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993;53:891-8.
10. Hickson JA, Huo D, Vander Griend DJ, et al. The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res 2006;66:2264-70.
11. Demicheli R, Pratesi G, Foroni R. The exponential-Gompertzian tumor growth model: data from six tumor cell lines in vitro and in vivo. Estimate of the transition point from exponential to Gompertzian growth and potential clinical implications. Tumori 1991;77:189-95.
12. Rygaard K, Spang-Thomsen M. Quantitation and gompertzian analysis of tumor growth. Breast Cancer Res Treat 1997;46:303-12.
13. Budzynski W, Radzikowski C. Cytotoxic cells in immunodeficient athymic mice. Immunopharmacol Immunotoxicol 1994;16:319-46.
14. Mule JJ, Jicha DL, Aebersold PM, et al. Disseminated human malignant melanoma in congenitally immune-deficient (bg/nu/xid) mice. J Natl Cancer Inst 1991;83:350-5.
15. De Feudis P, Vignati S, Rossi C, et al. Driving p53 response to Bax activation greatly enhances sensitivity to Taxol by inducing massive apoptosis. Neoplasia 2000;2:202-7.
16. Yaginuma Y, Westphal H. Abnormal structure and expression of the p53 gene in human ovarian carcinoma cell lines. Cancer Res 1992;52:4196-9.
17. Yaginuma Y, Hayashi H, Kawai K, et al. Analysis of the Rb gene and cyclin-dependent kinase 4 inhibitor genes (p16INK4 and p15INK4B) in human ovarian carcinoma cell lines. Exp Cell Res 1997;233:233-9.
18. Nakayama K, Nakayama N, Davidson B, et al. Homozygous deletion of MKK4 in ovarian serous carcinoma. Cancer Biol Ther 2006;5:630-4.
19. Lancaster JM, Dressman HK, Clarke JP, et al. Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 2006;16:1733-45.
20. Porras A, Zuluaga S, Black E, et al. P38 α mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli. Mol Biol Cell 2004;15:922-33.
21. Sarkar D, Su ZZ, Lebedeva IV, et al. mda-7 (IL-24) Mediates selective apoptosis in human melanoma cells by inducing the coordinated overexpression of the GADD family of genes by means of p38 MAPK. Proc Natl Acad Sci U S A 2002;99:10054-9.
22. el-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993;75:817-25.
23. Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-4.
24. Dulic V, Beney GE, Frebourg G, et al. Uncoupling between phenotypic senescence and cell cycle arrest in aging p21-deficient fibroblasts. Mol Cell Biol 2000;20:6741-54.
25. Noda A, Ning Y, Venable SF, et al. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994;211:90-8.
26. Macleod KF, Sherry N, Hannon G, et al. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev 1995;9:935-44.
27. Jost CA, Marin MC, Kaelin WG, Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 1997;389:191-4.
28. Chen CL, Ip SM, Cheng D, et al. P73 gene expression in ovarian cancer tissues and cell lines. Clin Cancer Res 2006;6:3910-5.
29. Dasari A, Bartholomew JN, Volonte D, et al. Oxidative stress induces premature senescence by stimulating caveolin-1 gene transcription through p38 mitogen-activated protein kinase/Sp1-mediated activation of two GC-rich promoter elements. Cancer Res 2006;66:10805-14.
30. Kim GY, Mercer SE, Ewton DZ, et al. The stress-activated protein kinases p38α and JNK1 stabilize p21(Cip1) by phosphorylation. J Biol Chem 2002;277:29792-802.
31. 1 regulation and tumor suppression. Gene 2004;336:1-13.
32. 1 arrest after γ-irradiation. Proc Natl Acad Sci U S A 1999;96:1002-7.
33. Chin YE, Kitagawa M, Su WC, et al. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 1996;272:719-22.
34. Choudhury AR, Ju Z, Djojosubroto MW, et al. Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nat Genet 2007;39:99-105.
35. 1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res 2005;65:3364-73.
36. Lee B, Kim CH, Moon SK. Honokiol causes the p21WAF1-mediated G(1)-phase arrest of the cell cycle through inducing p38 mitogen activated protein kinase in vascular smooth muscle cells. FEBS Lett 2006;580:5177-84.
37. Iiizumi M, Bandyopadhyay S, Watabe K. Interaction of Duffy antigen receptor for chemokines and KAI1: a critical step in metastasis suppression. Cancer Res 2007;67:1411-4.
38. Bandyopadhyay S, Zhan R, Chaudhuri A, et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat Med 2006;12:933-8.
39. Rinker-Schaeffer CW, Hickson JA. Stopping cancer before it colonizes. Nat Med 2006;12:887-8.